Results 101 to 110 of about 15,436 (169)

CMR and Amyloid Cardiomyopathy

JACC: Cardiovascular Imaging, 2014
Kwong, Raymond Y., Jerosch-Herold, Michael   +1 more
openaire   +1 more source

Temporal Trends in Incidence and Prevalence of Transthyretin Amyloid Cardiomyopathy in the United States. [PDF]

J Am Heart Assoc
Alexander KM, Dasgupta NR, Mathisen J, Møller SG, Tvistholm A, Maurer MS.   +5 more
europepmc   +1 more source

From stabilization to silencing in transthyretin amyloid cardiomyopathy: why sequencing should be treat-to-trajectory, not 'one-and-done'. [PDF]

Eur Heart J Cardiovasc Pharmacother
Albulushi A, Al Rashdi T, Al-Farhan H.
europepmc   +1 more source

Phenotypic Considerations for Tafamidis Use in a Real-World Cohort of Older Patients with Transthyretin Amyloid Cardiomyopathy. [PDF]

Cardiol Ther
Fumagalli C, Cappelli F, Maurer MS, Aus dem Siepen F, Dispenzieri A, Garcia-Pavia P, Hanna M, Carlsson M, Damy T.   +8 more
europepmc   +1 more source

Artificial Intelligence for the Diagnosis of Transthyretin Amyloid Cardiomyopathy: A Systematic Review of Machine Learning Application. [PDF]

Cardiol Res Pract
Jamileh E, Elmewafy AT, Qadeer MA, Zulfiqar Z, Kang K, Hosseini K, Antoun I.   +6 more
europepmc   +1 more source

Cardiac magnetic resonance T1 mapping for amyloid cardiomyopathy in patients with heart failure. [PDF]

Eur Heart J Imaging Methods Pract
Unger L, Gessner R, Stegmann T, Hagendorff A, Tiepolt S, Sabri O, Ebel S, Denecke T, Laufs U, Lavall D.   +9 more
europepmc   +1 more source

Sex Differences in a Contemporary, Real-World Cohort of Patients with Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis. [PDF]

Cardiol Ther
Fontana M, Aimo A, Grogan M, Crespo-Leiro MG, Maurer MS, Siepen FAD, Hanna M, Delgado D, Carlsson M, Damy T, Davis MK.   +10 more
europepmc   +1 more source

p.(V142I)-Associated Variant Transthyretin Amyloid Cardiomyopathy Complicating Complex Congenital Heart Disease: A Lethal Combination. [PDF]

JACC Case Rep
Zathar Z, Choy CH, Al-Sakini N, Pinney J, Banerjee P, Adamson DL, Gillmore JD, Fontana M, Steeds RP, Moody WE.   +9 more
europepmc   +1 more source

Reply: Causal Inference Challenges in Evaluating Baroreflex Activation Therapy for Transthyretin Amyloid Cardiomyopathy: A Critical Appraisal. [PDF]

JACC Case Rep
Khanna NR, DenDulk A, Atteya G, Talati SN.   +3 more
europepmc   +1 more source

Pathways for Patients with Transthyretin Amyloid Cardiomyopathy from a District General Hospital Perspective. [PDF]

J Cardiovasc Dev Dis
Kwok CS, Hamnett P, Palmer M, Chong D.
europepmc   +1 more source